Overview

Update
Total Equity Funding
$2M in 1 Round from 1 Investor
Most Recent Funding
$2M Series A on June 12, 2015
Headquarters:
Stony Brook, NY
Description:
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for multiple targets.
Founders:
, ,
Categories:
Biotechnology
Website:
http://codagenix.com
Social:

Company Details

Update

Codagenix Inc. utilizes our breakthrough platform technology termed SAVE to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method developed in the 1880s, pre-dating the discovery of the DNA double helix. Codagenix presents a breakthrough approach to live-attenuated vaccine design- were no longer would a vaccine developer blindly passage their target virus to construct a vaccine. The SAVE platform relies on synthetic biology and the “re-designing” of a target virus’s entire genome to yield a vaccine strain (Coleman JR. Science 2008; Muller SM. Nature Biotechnology 2010). This customization process uses software-based algorithms to ‘re-code’ the genome of a target virus. This genomic ‘re-coding’ results in a virus that is antigenically 100% identical (i.e. looks exactly like the wild-type, virulent strain) but possesses a genome that renders it attenuated in the host. The proteins of the SAVE-designed vaccine strain are one hundred percent identical to the virulent strain and as a result animals vaccinated with SAVE-designed vaccines develop a robust and protective immune response. SAVE is a platform technology that has had preliminary success constructing vaccine candidates for multiple, unrelated targets viruses. SAVE is an up-stream approach to vaccine construction. The science behind the SAVE ‘re-design’ targets a fundamental process of all viruses and thus it is viewed as platform that could yield a pipeline of candidate vaccine strains against multiple targets that include: Influenza A virus, Dengue Virus, Respiratory Syncytial virus, poliovirus, and others.

The first candidate virus in our pipeline is a live-attenuated Influenza A virus vaccine (LAIV), particularly the seasonal 2009 H1N1 Influenza A virus (referred to as “swine flu”). This candidate of our pipeline has been initially supported by a small business grant for $551,000 from the NIH that is eligible for $3.5 million based on success. Despite the availability of seasonal vaccines, Influenza still has a substantial impact on human health. Based on our approach and preclinical findings, Codagenix has the view that once in the market a SAVE-designed LAIV will prove superior to currently available seasonal flu vaccines. Aside from Influenza spreading around the world in seasonal epidemics, killing thousands of people annually, there is also a fear of a pandemic arising from an avian H5N1strain. An additional view of Codagenix is that SAVE can offer a rapid design of a highly immunogenic, anti-H5N1 vaccine should the need arise. The majority of seasonal Influenza A vaccines currently in the market at present are mostly composed of inactivated (killed) virus particles that can result in a inadequate immune response. There is an ever-growing demand in the market for influenza vaccines, thus an improved LAIV could capture significant market share of what is estimated to be a $6 billion market. In the US this market has been growing with compound annual growth rate (CAGR) of 19% and it is projected to retain a CAGR of 9% until 2015, at which the total market value would reach $15 billion.

The current business plan of Codagenix has two focuses – to prepare our LAIV for clinical testing and to further demonstrate that SAVE is a platform technology for vaccine development by expanding our pre-clinical pipeline to include other targets such as Dengue virus and RSV.

Funding Rounds (3) - $3.8M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2015$2M / Series A1
Jun, 2014$1.2M / Grant0
Jul, 2012$600k / Grant0

Investors (1)

InvestorRound(s)Partner(s)
Series A (Lead)-

Current Team (3)

Update

News (1)

Update
DateNews
Jun 12, 2015Long Island Newsday - LI biotech Codagenix receives $2M equity investment - Newsday

Offices/Locations (1)

Update
  • Headquarters

    25-108 Health Sciences Dr

    Stony Brook, NY 11794

    USA

Images (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos